Takai T, Yokota T, Yasue M, Nishiyama C, Yuuki T, Mori A, Okudaira H, Okumura Y
Bioscience Research and Development Laboratory, Asahi Breweries, Ltd., Ibaraki, Japan.
Nat Biotechnol. 1997 Aug;15(8):754-8. doi: 10.1038/nbt0897-754.
A major problem with allergen-specific immunotherapy involving repeated injection of allergens is the risk of an anaphylactic reaction. We engineered the major house dust mite allergen, Der f 2, to reduce its capacity to induce skin test reactivity and histamine release from peripheral blood basophils in allergic patients. The engineered allergen, in which the disulfide bond that linked the N- and C-terminal sequences of Der f 2 was disrupted, retained T-cell epitopes essential for immunotherapy and ability to stimulate T-cell proliferation. Such engineered allergens are potentially useful for safer and more effective immunotherapy for allergies.
涉及反复注射过敏原的过敏原特异性免疫疗法的一个主要问题是过敏反应的风险。我们对主要的屋尘螨过敏原Der f 2进行了改造，以降低其诱导皮肤试验反应性以及从过敏性患者外周血嗜碱性粒细胞释放组胺的能力。改造后的过敏原，其连接Der f 2的N端和C端序列的二硫键被破坏，保留了免疫疗法所需的T细胞表位以及刺激T细胞增殖的能力。这种改造后的过敏原对于更安全、更有效的过敏免疫疗法可能具有潜在用途。
